Advertisement

Bridging the Gap Between Experimental Animals and Humans in Osteosarcoma

  • Stephen J. Withrow
  • Chand Khanna
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 152)

Abstract

Osteosarcoma has been reported in virtually all species of mammals (mouse, rat, rabbit, wolf, monkey, cat, dog, horse, ferret, cow, grizzly bear, camel, polar bear, and more), reptiles, fish, birds, and dinosaurs. The pet dog with osteosarcoma shares many similarities with the human condition, including histology, local and metastatic progression, and response to conventional treatment modalities.1 These similarities, coupled with the high prevalence of osteosarcoma in pet dogs, provide important opportunities to improve our understanding of osteosarcoma biology and therapy through the study of this naturally occurring model (Table 1)2.

Keywords

Polar Bear Grizzly Bear Intact Immune System Canine Osteosarcoma Conventional Treatment Modality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dernell WS, Ehrhart NP, Straw RC, et al. Tumors of the Skeletal System. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen’s Small Animal Clinical Oncology. 4th ed. St Louis: Saunders Elsevier; 2007:540-582.CrossRefGoogle Scholar
  2. 2.
    Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147-156.CrossRefPubMedGoogle Scholar
  3. 3.
    Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma: dog vs. man. Clin Orthop. 1991;270:159-167.PubMedGoogle Scholar
  4. 4.
    Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet J. 1998;156:31-39.CrossRefPubMedGoogle Scholar
  5. 5.
    Misdorp W, Hart AA. Some prognostic and epidemiological factors in canine osteosarcoma. J Natl Cancer Inst. 1979;62:537-545.PubMedGoogle Scholar
  6. 6.
    Gellasch KL, Kalscheur VL, Clayton MK, et al. Fatigue microdamage in the radial predilection site for osteosarcoma in dogs. Am J Vet Res. 2002;63(6):896-899.CrossRefPubMedGoogle Scholar
  7. 7.
    Stevenson S, Holm RB, Pohler OEM, et al. Fracture-associated sarcoma in the dog. J Am Vet Med Assoc. 1982;180:1189.PubMedGoogle Scholar
  8. 8.
    Miller SC, Lloyd RD, Bruenger FW, et al. Comparisons of the skeletal locations of putative plutonium-induced osteosarcomas in humans with those in beagle dogs and with naturally occurring tumors in both species. Radiat Res. 2003;160(5):517-523.CrossRefPubMedGoogle Scholar
  9. 9.
    White RG, Raabe OG, Culbertson MR, et al. Bone sarcoma characteristics and distribution in beagles injected with radium-226. Radiat Res. 1994;137(3):361-370.CrossRefPubMedGoogle Scholar
  10. 10.
    McChesney-Gillette S, Gillette EL, Powers BE, et al. Radiation-induced osteosarcoma in dogs after external beam or intraoperative radiation therapy. Cancer Res. 1990;50:54-57.Google Scholar
  11. 11.
    Mayr B, Eschborn U, Loupal G, et al. Characterisation of complex karyotype changes in two canine bone tumours. Res Vet Sci. 1991;51(3):341-343.PubMedGoogle Scholar
  12. 12.
    Thomas R, Scott A, Langford CF, et al. Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res. 2005;15(12):1831-1837.CrossRefPubMedGoogle Scholar
  13. 13.
    Campbell SE, Nasir L, Argyle DJ, et al. Cloning of canine IL-1ra, TNFR and TIMP-2. Vet Immunol Immunopathol. 2001;78(2):207-214.CrossRefPubMedGoogle Scholar
  14. 14.
    Phillips JC, Stephenson B, Hauck M, et al. Heritability and segregation analysis of osteosarcoma in the Scottish deerhound. Genomics. 2007;90(3):354-363. Epub 2007 Jul 12.CrossRefPubMedGoogle Scholar
  15. 15.
    Sagartz JE, Bodley WL, Gamblin RM, et al. p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol. 1996;33(2):213-221.CrossRefPubMedGoogle Scholar
  16. 16.
    van Leeuwen IS, Cornelisse CJ, Misdorp W, et al. P53 gene mutations in osteosarcomas in the dog. Cancer Lett. 1997;111(1–2):173-178.PubMedGoogle Scholar
  17. 17.
    Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol. 2002;39(3):411-412.CrossRefPubMedGoogle Scholar
  18. 18.
    MacEwen EG, Pastor J, Kutzke J, Tsan R, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem. 2004;92(1):77-91.CrossRefPubMedGoogle Scholar
  19. 19.
    Owen LN. Transplantation of canine osteosarcoma. Eur J Cancer. 1969;5:615-620.PubMedGoogle Scholar
  20. 20.
    Wilson H, Huelsmeyer M, Chun R, et al. Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008;175:69-75.CrossRefPubMedGoogle Scholar
  21. 21.
    Barger AM, Fan TM, de Lorimier LP, et al. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats. J Vet Intern Med. 2007;21(2):8.Google Scholar
  22. 22.
    Fan TM, de Lorimier LP, Charney SC. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med. 2006;20(2):335-341.CrossRefPubMedGoogle Scholar
  23. 23.
    Jankowski MK, Steyn PF, Lana SE, et al. Nuclear scanning with 99 m-Tc-HDP for the initial evaluation of osseous metastasis in canine osteosarcoma. Vet Comp Oncol. 2003;1:152-158.CrossRefPubMedGoogle Scholar
  24. 24.
    Hillers KR, Dernell WS, Lafferty MHI, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc. 2005;226(8):1364-1367.CrossRefPubMedGoogle Scholar
  25. 25.
    Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc. 1998;213:1002-1006.PubMedGoogle Scholar
  26. 26.
    Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Rad Onc Biol Phys. 1990;18:1354-1357.Google Scholar
  27. 27.
    Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc. 2004;225(10):1548, 1567-1572.CrossRefPubMedGoogle Scholar
  28. 28.
    Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am. 1996;26:135-143.Google Scholar
  29. 29.
    Withrow SJ, Thrall DE, Straw RC, et al. Intra-arterial cisplatin with or without radiation in limbsparing for canine osteosarcoma. Cancer. 1993;71:2484-2490.CrossRefPubMedGoogle Scholar
  30. 30.
    Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer. 1991;67:126-134.CrossRefPubMedGoogle Scholar
  31. 31.
    Withrow SJ, Liptak J, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol. 2004;11(7):705-713.CrossRefPubMedGoogle Scholar
  32. 32.
    Berg J, Weinstein MJ, Springfield DS, et al. Response of osteosarcoma in the dog to surgery and chemotherapy with doxorubicin. J Am Vet Med Assoc. 1995;206(10):1555-1560.PubMedGoogle Scholar
  33. 33.
    Mauldin GN, Matus RE, Withrow SJ. Canine osteosarcoma treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Int Med. 1988;2:177-180.CrossRefGoogle Scholar
  34. 34.
    Kent MS, Strom A, Strom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med. 2004;18(4):540-544.CrossRefPubMedGoogle Scholar
  35. 35.
    Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for the treatment of metastatic canine osteosarcoma. Eur J Musculoskel Res. 1995;4:105-110.Google Scholar
  36. 36.
    MacEwen EG, Kurzmann ID, Rosenthal RC. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935-938.CrossRefPubMedGoogle Scholar
  37. 37.
    Lascelles BDX, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Annals of Surg Oncol. 2005;12(12):1073-1083.CrossRefGoogle Scholar
  38. 38.
    MacEwen EG, Kutzke J, Carew J, et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003;20(5):421-430.CrossRefPubMedGoogle Scholar
  39. 39.
    Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res. 2000;61(2):111-114.CrossRefPubMedGoogle Scholar
  40. 40.
    Wergin MC, Kaser-Hotz B, Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo. 2004;18(1):15-19.PubMedGoogle Scholar
  41. 41.
    Mullins MN, Lana SE, Dernell WS, et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med. 2004;18(6):859-865.CrossRefPubMedGoogle Scholar
  42. 42.
    Khanna C, Wan X, Bose S, et al. Ezrin, a Membrane - Cytoskeleton Linker, is Necessary for Osteosarcoma Metastasis. Nat Medicine. 2004;10(2):182-186.CrossRefGoogle Scholar
  43. 43.
    Flint AF, U’Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004;41(3):291-296.CrossRefPubMedGoogle Scholar
  44. 44.
    O’Brien MG, Straw RC, Withrow SJ, et al. Resection of pulmonary metastases in canine osteosarcoma: 36 cases (1983–1992). Vet Surg. 1993;22:105-109.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.College of Veterinary Medicine and Biomedical SciencesColorado State UniversityFt CollinsUSA
  2. 2.Comparative Oncology ProgramCenter for Cancer Research, National Cancer InstituteBethesdaUSA

Personalised recommendations